Xu Min, Li Honglin, Zhao Yiyan, Li Huimei, Zhao Chao, Zhang Xi, Ni Rong, Liang Jian, Xu Jinhuan
Reproductive Center, Huai'an First People's Hospital of Nanjing Medical University, Huaian, People's Republic of China.
Int J Womens Health. 2025 May 8;17:1313-1320. doi: 10.2147/IJWH.S517738. eCollection 2025.
Triptorelin acetate, leuprorelin and goserelin acetate were three commonly used gonadotropin-releasing hormone agonist (GnRH-a) formulations in IVF/ICSI-ET. However, current knowledge about the real-world effects on clinical outcomes of different GnRH-a formulations is limited. In this study, we aimed to compare the clinical outcomes of IVF/ICSI-ET using different GnRH-a formulations in long protocol during follicle phase.
This is a retrospective study. A total of 154 infertile women undergoing IVF/ICSI-ET in long protocol during follicle phase from September 2019 to December 2023 were assigned to three groups according to different GnRH-a formulations (A: triptorelin acetate; B: leuprorelin; C: goserelin acetate). The baseline information, ovulation induction outcomes and pregnancy outcomes were compared among three groups. Student's -test, Pearson Chi-Square test or Fisher's exact test was used for statistical analysis appropriately.
Groups A, B and C included 94, 36 and 24 patients, respectively. Compared with groups A and B, group C had significantly smaller total amount of gonadotropin (A vs B vs C: 2224.20±700.02 U vs 2266.67±884.01 U vs 1685.94±360.24 U) and shouter days of using gonadotropin (A vs B vs C: 11.61±1.91 days vs 11.83±2.48 days vs 9.50±0.98 days) (<0.05). Among the three groups, group C had the best pregnancy outcomes with the highest implantation rate (A vs B vs C: 40.4% vs 32.7% vs 41.9%), clinical pregnancy rate (A vs B vs C: 41.7% vs 39.4% vs 57.9%), live birth rate (A vs B vs C: 32.5% vs 33.3% vs 52.6%) and the lowest miscarriage rate (A vs B vs C: 22.9% vs 15.4% vs 9.1%).
Goserelin acetate was found to have good pregnancy outcomes in IVF/ICSI-ET with small amount and shout using days of gonadotropin, but there is a lack of statistical significance when compared to the pregnancy outcomes of triptorelin acetate and leuprorelin. The findings need future confirmation in larger trials or meta-analyses.
醋酸曲普瑞林、亮丙瑞林和醋酸戈舍瑞林是体外受精/卵胞浆内单精子注射-胚胎移植（IVF/ICSI-ET）中常用的三种促性腺激素释放激素激动剂（GnRH-a）制剂。然而，目前关于不同GnRH-a制剂对临床结局的实际影响的知识有限。在本研究中，我们旨在比较卵泡期长方案中使用不同GnRH-a制剂的IVF/ICSI-ET的临床结局。
这是一项回顾性研究。2019年9月至2023年12月期间，共有154名在卵泡期接受长方案IVF/ICSI-ET的不孕妇女根据不同的GnRH-a制剂分为三组（A组：醋酸曲普瑞林；B组：亮丙瑞林；C组：醋酸戈舍瑞林）。比较三组的基线信息、促排卵结局和妊娠结局。适当使用学生t检验、Pearson卡方检验或Fisher精确检验进行统计分析。
A组、B组和C组分别包括94例、36例和24例患者。与A组和B组相比，C组的促性腺激素总量显著更少（A组vs B组vs C组：2224.20±700.02 U vs 2266.67±884.01 U vs 1685.94±360.24 U），促性腺激素使用天数更短（A组vs B组vs C组：11.61±1.91天vs 11.83±2.48天vs 9.50±0.98天）（P<0.05）。在三组中，C组的妊娠结局最佳，着床率最高（A组vs B组vs C组：40.4% vs 32.7% vs 41.9%），临床妊娠率最高（A组vs B组vs C组：41.7% vs 39.4% vs 57.9%），活产率最高（A组vs B组vs C组：32.5% vs 33.3% vs 52.6%），流产率最低（A组vs B组vs C组：22.9% vs 15.4% vs 9.1%）。
在IVF/ICSI-ET中，发现醋酸戈舍瑞林使用促性腺激素的量少、天数短，妊娠结局良好，但与醋酸曲普瑞林和亮丙瑞林的妊娠结局相比，缺乏统计学意义。这些发现需要在更大规模的试验或荟萃分析中进一步证实。
